Compare AbCellera Biologics Inc (ABCL) vs Fox Corp Class B (FOX) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

FOX stock trades at $49.20, down 2.69% on the day, amid bearish technical signals and recent volatility following its $22 billion Roku acquisition announcement. The company shows strong fundamental performance with three consecutive quarterly earnings beats, revenue growth to $16.3 billion in 2025, and improved cash flow generation. However, technical indicators signal bearish momentum with the stock trading near support levels while analyst sentiment remains mixed with 43% buy ratings.

The outlook balances strong operational execution against acquisition integration risks. FOX's attractive valuation (P/E 13.14) and streaming expansion through Roku present growth opportunities, but high leverage and competitive pressures create near-term uncertainty. Investor focus remains on Q2 2026 earnings delivery and Roku synergy realization timelines.